ALFA Finder| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 15% YoY growth to ₹260.8 Cr; robust organic expansion. |
|---|---|
| Margins | Expansion to 18%+ EBITDA due to better product mix. |
| Demand visibility | Strong traction in critical care, fertility, and aesthetics segments. |
| Management confidence | High, focusing on Indore utilization and complex injectable leadership. |
Growth
Revenue grew 15% YoY to ₹260.8 Cr; EBITDA margins improved significantly to 18.09% from 14.6%.
Outlook
Management maintains 15-20% YoY revenue growth guidance with EBITDA margins expected to sustain at 18-20%.
Risks
High dependence on Indore plant utilization and EU certification timelines for export margin expansion.
Last quarter's promises, checked
Delivered
- Guided 30% Indore utilization by year-end → delivered 30% (= BEAT)
- Guided Indore EBITDA breakeven by Q4 → delivered Breakeven (= BEAT)
- Guided 15% YoY revenue growth → delivered 15% (= BEAT)
Partly delivered
- Guided 0.5-1% gross margin expansion → delivered 18.09% EBITDA margin (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹478.55
- Market cap
- ₹4,799 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 65.3×Sector 43.8×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr